Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 103Lung Neoplasms 39Neoplasms 11Neoplasm Metastasis 11Colorectal Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 6Pancreatic Neoplasms 6Mesothelioma, Malignant 5Mesothelioma 5Carcinoma 5Ovarian Neoplasms 4Meningeal Carcinomatosis 4Melanoma 4Colonic Neoplasms 4Advanced Solid Tumors 4Rectal Neoplasms 3Adenocarcinoma of Lung 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Non-squamous Non-small Cell Lung Cancer 2Neoplasms by Site 2Lung Diseases 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Pancreatic Ductal 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Brain Neoplasms 2

Interventions

cemiplimab 1Pemetrexed 1Paclitaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Non-small Cell Lung Cancer × Pemetrexed × 90 days × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡